New drug combo aims to disarm severe food allergies
NCT ID NCT06369467
Summary
This is a very early safety study testing an experimental drug called linvoseltamab, given alongside an existing allergy drug (dupilumab), in adults with severe, life-threatening food allergies. The goal is to see if this combination is safe and can reduce the levels of the specific antibodies (IgE) that cause dangerous allergic reactions. Only 6 participants will be enrolled to first check for side effects and how the body handles the drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinica Universidad de Navarra - Madrid
WITHDRAWNMadrid, 28027, Spain
-
Clinica Universidad de Navarra- Pamplona
WITHDRAWNPamplona, 31008, Spain
-
Emory University- Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
The Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
University of South Florida
RECRUITINGTampa, Florida, 33613, United States
Conditions
Explore the condition pages connected to this study.